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CLINICAL RESEARCHPretreatment C-Reactive Protein Is a Predictor for
Outcomes after Reduced-Intensity Allogeneic
Hematopoietic Cell Transplantation
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We tested the independent prognostic impact of 2 commonly used biomarkers, C-reactive protein (CRP)
and interleukin (IL)-6, on the outcomes of allogeneic hematopoietic cell transplantation (HCT). Consecutive
patients who underwent a uniform reduced-intensity conditioning (RIC) regimen of fludarabine (Flu), mel-
phalan (Mel), and alemtuzumab were evaluated retrospectively. Cryopreserved serum samples drawn before
the RIC were available to measure CRP levels in 81 patients and IL-6 levels in 79 patients. Patients with CRP
levels above the median of 18.5 mg/L had significantly more grade 3-4 hepatic toxicity (P5 .01), longer HCT
hospital stay (P5 .005), more acute graft-versus-host disease (aGVHD) (P5 .003), greater nonrelapse mor-
tality (NRM) (P5 .01), and inferior overall survival (OS; P5 .02). Higher baseline CRP showed no significant
correlation with grade 3-4 infectious toxicity (P 5 .09). In contrast to CRP, pre-HCT IL-6 levels above the
median of 78.3 pg/mL did not confer a statistically significant increased risk of toxicity or mortality. An ele-
vated HCT comorbidity index (HCT-CI) did not predict for anymeasure of HCTmorbidity. After adjustment
for disease status, comorbidity, performance status, and age, elevated CRP concentration remained predic-
tive of NRM. These data require confirmation in non–T cell–depleted conditioning regimens. If validated,
they suggest that preconditioning CRP holds promise for enhancing estimates of transplantation tolerance.
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Numerous advances, including but not limited to
reduced-intensity conditioning (RIC), have allowed
extension of allogeneic hematopoietic cell transplanta-
tion (HCT) to older and less healthy individuals. Even
after RICHCT,morbidity andmortality can be consid-
erable, with reported rates ranging from 10% to 40%
[1-4]. In addition to age, comorbidity scores and perfor-
mance status have emerged as powerful prognostic fac-
tors for HCT complications [1,2,5,6]; for example, the
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doi:10.1016/j.bbmt.2008.08.004HCT comorbidity index (HCT-CI) has gained accep-
tance as a useful tool for measuring comorbidity and es-
timating nonrelapse mortality (NRM) [6,7]. More
reproducible, less complex tools are still needed to bet-
ter predict HCT-related complications and appropri-
ately balance the benefits of disease control against
potentially serious regimen-relatedmorbidity andmor-
tality, particularly in older and/or less fit patients.
Serum inflammatory biomarkers have emerged as
powerful prognostic factors for outcome in various
settings. C-reactive protein (CRP) and interleukin
(IL)-6 are 2 of the most commonly analyzed serum
biomarkers. IL-6 is a proinflammatory cytokine that
mediates systemic inflammation [8]; CRP is a hepati-
cally synthesized acute-phase reactant. Higher serum
concentrations of CRP and IL-6 independently pre-
dict poor functional status [9-13], increased risk of car-
diovascular outcomes [14,15], and death [16-18]. The
prognostic value of higher CRP levels also applies to
cancer patients [19,20]. Preliminary evidence suggests
that rising or elevated inflammatory biomarkers after
HCT conditioning may be predictive of HCT-related
complications [21-24] and relapse [25].1209
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tic importance of inflammatory biomarkers before
HCT conditioning has not yet been well described.
Consequently, in this work we examined the indepen-
dent impact of preconditioning CRP and IL-6 level on
HCT outcomes.
MATERIALS AND METHODS
We hypothesized that elevated levels of precondi-
tioning serum inflammatory biomarkers would be pre-
dictive of increasedNRMand reducedHCTtolerance.
In this retrospective analysis, we analyzed 112 consec-
utive patients enrolled in a prospective trial using an
RIC allograft with in vivo T cell depletion for hemato-
logic malignancies [26]. In an earlier report, we
described the impact of performance status and the
Kaplan-Feinstein comorbidity scale on outcome in
a subset of these patients [5].
Details of the conditioning regimen and support-
ive care have been published previously [26]. The pre-
parative regimen comprised 5 days of fludarabine
(Flu), 30 mg/m2/day i.v. (150 mg/m2 total), and alem-
tuzumab, 20 mg/day i.v. (100 mg total), followed by
melphalan (Mel), 140 mg/m2 i.v. Tacrolimus was ad-
ministered for posttransplantation immunosuppres-
sion. Allografts were obtained from granulocyte
colony-stimulating factor (G-CSF)–mobilized periph-
eral blood stem cells (PBSCs), except in 7 unrelated
donors (6% of all donors) who requested a marrow
harvest. All patients were hospitalized for the prepara-
tive regimen and for the immediate posttransplanta-
tion care. Patients were discharged after neutrophil
engraftment and when medically stable. The Univer-
sity of Chicago’s Institutional Review Board approved
the study protocol, and all patients provided written
informed consent.
Pretransplantation Comorbidity Assessment
and Performance Score
Comorbidity was tabulated using the HCT-CI as
published by Sorror et al. [6]. Following this classifica-
tion scheme, scores of $ 3 are categorized as high
comorbidity and scores \ 3 as low comorbidity.
Pre-HCT performance status (PS) was assigned an
Eastern Cooperative Oncology Group PS score of
0 to 4. Because protocol eligibility required a score
of # 2, values are restricted to 0, 1, or 2.
Transplantation-Related Morbidity
Morbidity was measured through day 100 by tabu-
lating the duration of initial hospitalization, grade 3 or
greater infectious and hepatic toxicities, and acute
graft-versus-host disease (aGVHD). Data on infec-
tious and hepatic toxicities were obtained by reviewing
the medical records, focusing on grade 3 or greatertoxicity, following the National Cancer Institute’s
Common Toxicity Criteria (http://ctep.cancer.gov/
forms/CTCAEv3.pdf). The aGVHD grading fol-
lowed published criteria [27] and was assigned up to
day 100. NRM was defined as death without disease
progression.
Biomarkers
Inflammatory biomarkers were assayed from
cryopreserved serum obtained 2 weeks or less before
transplantation conditioning using enzyme-linked im-
munosorbent assay (ELISA) following the manufac-
turers’ guidelines. CRP was quantified using the
CRP Quantitative Assay (Biomeda, Burlingame, CA);
the manufacturer’s reference range is 0 to 8.00 mg/L.
IL-6 (in pg/mL) was measured using the TiterZyme
ELISA system (Assay Designs, Ann Arbor, MI).
Statistical Analysis
Wilcoxon’s rank-sum test was used to compare
continuous variables between groups, because most
variables were not normally distributed. The c2 test
or Fisher’s exact test was used to compare proportions
between groups. For ease of interpretation, CRP and
IL-6 levels were dichotomized at the median, but the
effect of log-transformed values on outcome was ex-
plored as well. The date of the stem cell infusion was
considered day 0 for all time-to-event analyses except
for the length of hospital stay, where the day of hospi-
talization for conditioning represented day 0. Overall
survival (OS) probabilities were estimated using the
method of Kaplan and Meyer [28], and OS was com-
pared between groups using the log-rank test. Cox
proportional hazards models were used for univariate
analysis of continuous predictor variables, as well as
for multivariate analyses. Estimated hazard ratios
(HRs), along with 95% confidence intervals (CIs)
and P values, are reported based on Cox regression
[29]. Cumulative incidence estimates were obtained
using the competing-risks approach, with deaths oc-
curring before the event of interest (eg, relapse, mor-
bidity) treated as competing events [30]. To account
for competing risks, Cox proportional hazards models
were used, as described by Lunn and McNeil [31]. All
statistical analyses were done using Stata version 9
(StataCorp, College Station, TX) and R (http://
www.r-project.org/).
RESULTS
Table 1 summarizes the baseline characteristics of
our subjects. The median age was 52 years (range, 19
to 70 years), and acute myelogenous leukemia
(AML)/myelodysplastic syndrome (MDS) was the
most frequent indication for HCT. High comorbidity
(ie, HCT-CI$ 3) was seen in 42% of the subjects, and
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vivors was 42 months.
Biomarkers
Cryopreserved serum samples drawn before HCT
conditioning were available for analysis of CRP levels
in 81 patients (72%) and IL-6 levels in 79 patients
(71%). In 2 patients, the samples were insufficient
to also analyze IL-6 levels. The coefficient of varia-
tion for CRP and IL-6 levels was 4.6% and 4.9%, re-
spectively. CRP levels ranged from 0.17 to 180 mg/L,
with a mean of 40.5 6 1.7 mg/L and a median of 18.5
Table 1. Baseline Characteristics of Subjects (n 5 112)
Characteristic Value (%)
Median age at transplantation, years 52
Age $ 50 years 67 (60)
Disease
AML/MDS 65 (58)
Non-Hodgkin lymphoma and Hodgkin lymphoma 18 (16)
Chronic lymphocytic leukemia 3 (3)
Acute lymphoblastic leukemia 4 (4)
Chronic myelogenous leukemia 4 (4)
Myeloma 3 (3)
Other* 11 (7)
Active disease at transplantation 52 (46)
Donor type
Matched related (n 5 64) or unrelated (n 5 39) 103 (92)
One antigen/allele mismatched related (n 5 4)
or unrelated (n 5 5)
9 (8)
Comorbidity by HCT-CI
0 31 (28)
1-2 34 (30)
$ 3 47 (42)
PS score
0 76 (68)
1 26 (23)
2 10 (9)
Biomarkers†
CRP, mg/L
Median 18.5
Mean 40.5
IL-6, pg/mL
Median 78.3
Mean 123
*Other disease includes aplastic anemia and/or paroxysmal nocturnal
hemoglobinuria (PNH) (n 5 3), chemotherapy-induced aplasia (n 5
1), mast cell leukemia (n 5 2), dendritic cell tumor (n 5 1), sickle cell
anemia (n 5 1), myelofibrosis (n 5 2), and prolymphocytic leukemia
(n51).
†CRP level was measured in 81 patients; IL-6 level, in 79 patients.mg/L. IL-6 level ranged from 10 to 2258 pg/mL,
with a mean of 123 pg/mL and a median of 78.3
pg/mL.
Elevated CRP level demonstrated a positive corre-
lation with active disease status at transplantation (P5
.059) and lower PS (P5 .019). No correlation was seen
between CRP level and the HCT-CI (P 5 .64) or
recipient age (P 5 .94). IL-6 level was not correlated
with disease status at transplantation (P 5 .60), PS (P
5 .48), older age (P 5 .82), or high HCT-CI (P 5
.24). There was no significant correlation between
high HCT-CI and active disease at HCT (P 5 .18).
Outcomes
The median and mean durations of hospitalization
for transplantation were 23 and 27 days. By day 100,
the cumulative incidence of grade 3-4 infectious toxic-
ities was 50% (95% CI 5 40% to 59%), and the inci-
dence of hepatic toxicities was 30% (95%CI5 22% to
39%). The cumulative day 100 incidence of grade
II-IV aGVHD was 24% (95% CI 5 17% to 32%).
NRM was 17% at day 100 (95% CI 5 11% to 25%)
and 23% at day 180 (95% CI 5 16% to 31%). Esti-
mated OS was 83% at day 100 (95% CI 5 75% to
89%), 78% at day 180 (95% CI 5 61% to 78%), and
55% at 1 year (95% CI 5 45% to 64%).
Prognostic Factors: Univariate Analysis
Table 2 summarizes the univariate analysis of the
effect of standard prognostic factors on transplanta-
tion-related morbidity and mortality. Donor type
was not included in this analysis, because our previous
analysis using this conditioning regimen demonstrated
no difference between unrelated and related donors on
outcome (P 5 .99) [5]. Donor mismatch was excluded
because of the low number of patients (n 5 9).
Toxicity
Elevated CRP level above the median was gener-
ally predictive of morbidity and mortality after HCT
in univariate analysis (Table 2; Figure 1). Elevated
CRP demonstrated no statistically significant associa-
tion with infectious toxicities (P 5 .09). Higher CRP
levels conferred an increased risk of hepatic toxicities,Table 2. Univariate Association of Prognostic Factors and Transplantation Outcomes
Grade 3 or 4 Toxicity by day 100
Infection Hepatic Duration of Hospital Stay aGVHD NRM OS
Factor HR P HR P HR P HR P HR P HR P
Age $ 50 years 0.84 .52 1.1 .81 1.3 .19 0.98 .95 2.0 .06 1.8 .02
Active disease 1.2 .53 1.5 .30 1.9 .001 0.70 .33 2.2 .03 3.1 < .001
HCT-CI $ 3 0.97 .92 1.0 .93 1.4 .11 0.65 .27 1.4 .37 2.0 .004
PS $ 1 1.0 .91 2.0 .05 1.4 .10 2.4 .02 3.6 < .001 2.5 < .001
CRP above median 1.8 .09 3.1 .01 2.0 .005 4.1 .003 3.1 .01 2.0 .02
IL-6 above median 1.5 .24 1.9 .14 1.3 .27 1.3 .75 1.7 .22 1.3 .41
1212 Biol Blood Marrow Transplant 14:1209-1216, 2008A. S. Artz et al.Figure 1. The impact of pre-transplantation C-reactive Protein (CRP) above and below the median is shown on the cumulative incidence of grade 3-4
infections, grade 3-4 infections, grade 3-4 hepatic toxicities, duration of the initial transplantation hospital stay, grade 2-4 acute graft-versus-host disease,
non-relapse mortality, and overall survival.longer initial transplantation hospitalization, and
more grade II-IV aGVHD. Only 8 out of 112
patients had grade 3-4 aGVHD, and 5 of the 6 with
evaluable CRP data had an elevated CRP level. In con-
trast, as shown in Table 2, an elevated IL-6 level before
HCT conditioning was not associated with worse
outcome. The limited number of events for these
morbidity measures precluded multivariate analysis.
NRM and OS
Univariate analyses of potential predictors of
NRM and OS are reported in Table 2. Patients with
elevated CRP level were more likely to suffer NRM
(HR 5 3.1; 95% CI 5 1.3 to 7.5) and worse OS.
The association with NRM persisted when the
log-transformed CRP variable was used (P 5 .03).
The cumulative incidence of NRM by day 180 for
patients with higher CRP level was 32%, as opposed
to only 10% for those with lower CRP levels(P5 .013). In contrast, high IL-6 level was not associ-
ated with greater NRM or worse OS. Similarly, no
association was found between log-transformed IL-6
and NRM (P5 .63). An additional analysis of patients
with both CRP and IL-6measurements (n5 79) found
that 32% of the evaluable patients had elevated levels
of both biomarkers above the median (data not
shown). This dual–elevated biomarker phenotype
was strongly associated with an increased risk of
NRM (P 5 .0087). Although elevated biomarkers
were correlated with active disease at HCT, higher
biomarker levels were not associated with increased
disease-related deaths (P5 .42 for elevated CRP level;
P 5 .98 for elevated IL-6 level). These results suggest
that the prognostic relevance of biomarkers was
restricted primarily to transplantation-related toxicity
rather than to relapse.
Among other prognostic factors, worse PS score
(P 5 .0001) and active disease status (P 5 .03) were
associated with NRM, whereas high HCT-CI score,
Biol Blood Marrow Transplant 14:1209-1216, 2008 1213CRP Predicts Outcomes after RIC Allogeneic HCTolder age, and mismatched donor at HCT were not.
All of the prognostic markers demonstrated a strong
association with worse OS.
Multivariate Analysis
The independent effect of each biomarker on
NRM and OS was assessed, adjusting for age, HCT-
CI, PS, and active disease at transplantation (Table
3). Elevated CRP level continued to predict NRM (P
5 .04) but was not statistically associated with worse
OS (P 5 .09). IL-6 level showed no significant effect
on NRM or OS. The phenotype of dual biomarker
elevation (ie, both IL-6 and CRP levels above the
median) was associated with a significantly heightened
risk of NRM in multivariate analysis (P 5 .007).
DISCUSSION
Such advances as RIC and improved supportive
care have led to a gradual loosening of HCT eligibility
criteria and, consequently, an expanding pool of older
and less healthy HCT candidates [32]. Even after RIC
in relatively select individuals, NRM varies widely [1-
4,33]. This dilemma has generated widespread interest
in findingmore accurate pretransplantationmarkers of
tolerance and NRM. Several previous studies have
shown that comorbidity and performance status are
useful but crude tools [1,2,5,6], suggesting the need
for additional prognostic markers of tolerance.
Inflammatory biomarkers, such as CRP and IL-6,
have emerged as promising prognostic factors for
numerous health outcomes in nontransplantation
cohorts. HCT studies have focused on inflammatory
biomarkers postconditioning and/or evaluated serially
to predict outcome [34,35]. Higher levels post-HCT
have been associated with increased transplantation-
related complications in some studies [34,36,37] and
with worse survival in others [24,38]. Schots et al.
[21] analyzed IL-6, IL-8, and tumor necrosis factor-
a levels serially in 84 patients after HCT and found
that elevated inflammatory markers early after trans-
plantation were predictive of major complications.
Min et al. [25] reported an association between lower
mean CRP levels after HCT with decreased GVHD
and increased disease relapse. In the largest series re-
Table 3. Multivariate Analysis of Prognostic Factors
NRM OS
Characteristic HR 95% CI P HR 95% CI P
Age $ 50 years 1.2 0.52-3.0 .68 1.2 0.6-2.1 .63
Disease status (active) 1.6 0.71-3.8 .24 2.6 1.4-4.8 .002
HCT-CI $ 3 1.0 0.42-2.3 .98 1.8 0.98-3.2 .06
PS $ 1 2.1 0.91-4.8 .08 1.5 0.97-2.2 .07
CRP above median* 2.5 1.0-6.3 .04 1.7 0.93-3.1 .09
IL-6 above median* 1.2 0.73-4.2 .19 1.2 0.67-2.3 .50
*Multivariate models include 1 biomarker, either CRP or IL-6.ported to date (224 patients), Fuji et al. [24] found
that higher peak CRP levels after conditioning
correlated with increased aGVHD, infections, and
NRM. Decisions about whether to proceed to HCT,
as well as about modifications to the conditioning
regimen or treatment plan, mandate pretreatment
risk assessment rather than biomarker kinetics after
conditioning.
To the best of our knowledge, this is the first
study to assess the independent prognostic value of
proinflammatory biomarkers measured before HCT
conditioning on outcome. We found that elevated
levels of CRP, but not of IL-6, were predictive of
increased morbidity and mortality. Higher CRP
levels predicted worse tolerance, including hepatic
toxicity, duration of transplantation hospitalization,
aGVHD, NRM, and OS. Higher CRP also tended
to track with severe GVHD; an elevated CRP level
was found in 5 of the 6 patients with grade III-IV
aGVHD and baseline CRP measurements. Infectious
toxicity was the sole outcome measure not associated
with higher baseline CRP levels (P 5 .09). The affect
on NRM persisted after adjusting for other standard
prognostic variables, including the HCT-CI. In con-
trast, elevated IL-6 level did not demonstrate a statis-
tically significant association with worse outcome.
The biomarkers’ effects appeared to be restricted to
toxicity and death resulting from NRM; neither bio-
marker influenced death from disease relapse. These
findings suggest that CRP may be a relatively specific
marker of HCT tolerance.
The reason for the worse outcomes in patients with
elevated baseline CRP level remains unclear. Besides
measuring the inflammatory cascade, CRP also has
direct proinflammatory and anti-inflammatory prop-
erties [39,40]. It could be postulated that pretrans-
plantation inflammation increases susceptibility to
regimen-related toxicity and the deleterious effects of
GVHD. A simpler, albeit incomplete, explanation
may be that CRP represents a general measure of
health status; for example, CRP level, independent of
comorbidity, is associated with disability and dimin-
ished function in older adults [41,42]. The correlation
between higher CRP level and lower PS score (P 5
.019), along with the absence of correlation between
CRP level and comorbidity or age, further support
this hypothesis. Regardless, this readily available and
inexpensive biomarker was found to predict NRM
independent of standard prognostic factors, suggesting
a promising role in pretransplantation evaluation. A
more puzzling question is why IL-6 did not confer
similar adverse risks as elevated CRP levels, because
IL-6 serves as a potent and rapid stimulus of CRP syn-
thesis [8]. The better predictive capacity of CRP level
may reflect the specific and amplified role of CRP as
a downstreamproduct of inflammation. IL-6 is a highly
regulated proinflammatory cytokine with pleiotropic
1214 Biol Blood Marrow Transplant 14:1209-1216, 2008A. S. Artz et al.effects [43]. Compared with CRP, IL-6 has multiple
stimuli, changes less dramatically in response to in-
flammation, and exhibits a diurnal variation, all of
which may obscure the prognostic impact [44].
The greatest limitation of the present study is re-
lated to generalizability, because we used a nonmyeloa-
blative T cell–depleted regimen.Other limitations also
should be noted. The normal range of CRP depends
on the population evaluated, with levels between\ 3
and\10mg/L considered normal [45,46]. In the pres-
ent study, the median level was quite high (18 mg/L).
In a recent study evaluating CRP kinetics among
HCT patients, the median baseline CRP level was
much lower (3 mg/L), although the baseline range of
0 to 200 mg/L was comparable to that in our patients
(0.17 to 180 mg/L) [24]. Likewise, IL-6 levels were
markedly elevated in our study, with a median of 78
pg/mL, compared with median levels of 2 to 4 pg/
mL derived from epidemiologic surveys in other co-
horts [15,16,47]. For clinical simplicity, in this explor-
atory analysis, biomarker values were dichotomized
above and below the median. The refinement of
thresholds or categorization schemes (eg, quartiles)
in future studies may allow better prognostic discrim-
ination. We believe that analyzing levels at a standard-
ized time point in a homogeneous group of patients
(eg, analyzing CRP levels evaluated 2 weeks after
achieving first remission among HCT-eligible AML
patients) may further clarify the prognostic potential.
Although IL-6 levels did not affordmuch value as a sin-
gle predictor, a strong association with NRM, beyond
that found for higher CRP levels alone, was detected in
those patients with higher levels of both IL-6 and
CRP. For this reason, future validation studies should
include both IL-6 and CRP levels. Many other inflam-
matory markers studied in other settings, including
cystatin-C, pro-calcitonin, serum amyloid A, tumor
necrosis factor-a, and IL-8, also merit investigation.
Because wemeasured multiple domains of toxicity,
our study supplements the growing literature on prog-
nostic factors for HCT tolerance. We again note, as
reported previously, that worse performance status is
predictive of NRM and OS [5]. We also found that
higher comorbidity, as evaluated by the Kaplan-Fein-
stein scale, functioned as a weak prognostic factor.
Sorror and colleagues [6,7] recently developed the
HCT-CI, a more sensitive comorbidity measure than
the Kaplan-Feinstein scale. In a recent update of 408
patients undergoing nonmyeloablative conditioning,
that group confirmed that high HCT-CI score and
lower PS score adversely affected morbidity, NRM,
and OS [48].
Surprisingly, we found no significant predictive
value of the HCT-CI for toxicity or NRM (HR 5
1.4; P 5 .37). The reason for these discordant results
remains unclear, although preliminary data from an-
other institution also found that PS, but not highHCT-CI, predicted for NRM [49]. We recently re-
ported that the addition of alemtuzumab to Flu and
Mel for in vivo T cell depletion reduced organ toxicity
and GVHD at the expense of relapse, compared with
the same regimen without alemtuzumab [50]. The
alemtuzumab-containing regimen may have dimin-
ished the affect of preexisting comorbidity and organ
dysfunction on NRM [26,51]. This possibility raises
the intriguing hypothesis that a low-toxicity, low-
GVHD regimen, such as Flu, Mel, and alemtuzumab,
may be beneficial for patients with significant comor-
bidity. This should not diminish enthusiasm for the
HCT-CI, however; in our series, the HCT-CI still
predicted for worse OS and may be valuable for antic-
ipating tolerance for regimens incorporating standard
GVHD prophylaxis.
In conclusion, elevated CRP level, but not IL-6
level, before HCT conditioning independently
predicted for increased toxicity and NRM after alloge-
neic HCT using a RIC regimen with in vivo T cell
depletion. Our data require confirmation in patient
populations receiving other conditioning regimens
and methods of GVHD prophylaxis. If the data were
validated, then CRP could be rapidly integrated into
risk assessment tools before transplantation and may
provide a simple and inexpensive test to promote com-
parisons across study cohorts and within registry stud-
ies. Arming clinicians andpatientswith a reliablemeans
to estimate morbidity and mortality may facilitate
transplantation decision making and permit testing
therapeutic strategies that optimally balance HCT-
relatedmorbidity andmortality against disease relapse.
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